Double-dose intravitreal faricimab in resistant neovascular age-related macular degeneration: safety and efficacy
Anti-VEGF therapy remains the mainstay treatment for neovascular age-related macular degeneration (nAMD), yet a subset of eyes exhibit resistance to standard treatment regimens. This study evaluates the safety and efficacy of double-dose intravitreal faricimab (12 mg) in a series of eyes with nAMD refractory to b...